News Sentiment

BIO sentiment intelligence

Bio-Rad Laboratories Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 50 Balanced news tone 50 relevant articles
Exchange NYSE United States
Sector Healthcare Market context
Industry Medical Devices Read-through group
Latest close 296.11 Week of 10 Jul 2026
Weighted tone 50/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Earnings

75/100 classification confidence.

Company focus 41

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

-0.3% over one week, +3.6% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Neutral

Abbott Laboratories stock trades steadily as diagnostics and medical devices support earnings

Market Reaction

Balanced read

46/100 confidence

News tone and price action are not far from neutral.

Primary event Earnings 75/100 classification
One-week reaction -0.3% Price digesting
Trend fit Trend inactive 3.6% over four weeks
Fair value -2.6% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 8
Neutral 33
Negative 9

Relevance

Why the article matched

Direct first
Direct company coverage 41
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 12
Sahm 11
TradingView 6
Stock Titan 5
Ad Hoc News 3
StockStory 3
Stock Traders Daily 3
FinancialContent 2

Event Lens

What the news is about

Classified themes
Earnings 23
Market update 15
Deals and strategy 4
Analyst action 3
Guidance 3
Balance sheet 2

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 50
Sahm Direct company coverage

Bio Rad Laboratories (BIO) Launches New ddPCR Kits Following A Fair Value Debate

Bio-Rad Laboratories (BIO) has launched new QX700 System-compatible Vericheck ddPCR Kits for quality control in cell and gene therapy, potentially impacting investor assessment of the stock. While the company's shares show modest recent momentum and analyst targets are largely me

Tone
Neutral 50/100
Event
Analyst action
Published
13 Jul 2026 02:40
Source
Sahm
Sahm Direct company coverage

Bio Rad Laboratories (BIO) Following ddPCR Expansion Narrative Looks Fully Valued

Bio-Rad Laboratories (BIO) has experienced recent stock momentum, with shares up 6.5% over the past week, although it's still down 54.9% over five years. The stock currently trades slightly above its narrative fair value of $293, driven by expectations of growth from its ddPCR pl

Tone
Negative 40/100
Event
Market update
Published
29 Jun 2026 21:39
Source
Sahm
TradingView Direct company coverage

Bio-Rad Laboratories, Inc. Class B Actuals & Estimates (LSX:862449)

This article provides an overview of Bio-Rad Laboratories, Inc. Class B (LSX:862449) financial data, analyst estimates, and frequently asked questions. It details past earnings, revenue, net income, and future earnings expectations, along with share price forecasts from analysts.

Tone
Neutral 50/100
Event
Earnings
Published
27 Jun 2026 09:41
Source
TradingView
TradingView Direct company coverage

Bio-Rad Laboratories, Inc. Class B Actuals & Estimates (FWB:BUW)

This article provides financial actuals and estimates for Bio-Rad Laboratories, Inc. Class B (FWB: BUW), detailing income statement, balance sheet, cash flow, and valuation metrics. It includes analyst forecasts, historical price movements, earnings reports, dividend policy, empl

Tone
Neutral 50/100
Event
Earnings
Published
25 Jun 2026 23:41
Source
TradingView
TradingView Direct company coverage

Bio-Rad Laboratories, Inc. Class A Actuals & Estimates (NYSE:BIO)

This article provides an overview of Bio-Rad Laboratories, Inc. (NYSE: BIO) stock, including its current price, market capitalization, and historical performance. It also details actual and estimated financial data, analyst forecasts for its future price, and information regardin

Tone
Neutral 50/100
Event
Analyst action
Published
25 Jun 2026 21:41
Source
TradingView
Stock Traders Daily Direct company coverage

Price-Driven Insight from (BIO) for Rule-Based Strategy

This article provides a price-driven analysis for Bio-rad Laboratories Inc. Class A (NYSE: BIO), highlighting weak near and mid-term sentiment, but a neutral long-term outlook. It identifies a significant risk-reward short setup and outlines three distinct AI-generated trading st

Tone
Negative 39/100
Event
Guidance
Published
25 Jun 2026 02:32
Source
Stock Traders Daily
Stock Traders Daily Direct company coverage

(BIO) as a Liquidity Pulse for Institutional Tactics

This article provides a detailed analysis of Bio-Rad Laboratories Inc. Class A (NYSE: BIO), highlighting its potential as a liquidity pulse for institutional tactics. It identifies a strong risk-reward setup targeting a 12.2% gain against 0.3% risk and outlines three distinct AI-

Tone
Positive 73/100
Event
Balance sheet
Published
03 Jun 2026 22:09
Source
Stock Traders Daily
Stock Titan Direct company coverage

[144] BIO-RAD LABORATORIES, INC. SEC Filing

This SEC Filing (Form 144) for Bio-Rad Laboratories, Inc. (BIO) discloses a proposed sale of 700 shares of Class A Common stock by Alice Schwartz, acquired via donation on December 10, 2018. The aggregate market value of these shares is $219,296.44, to be sold on the NYSE on or a

Tone
Neutral 50/100
Event
Market update
Published
28 May 2026 18:40
Source
Stock Titan
Stock Titan Direct company coverage

Morgan Stanley files Rule 144 notice to sell 550 BIO shares (NYSE: BIO)

Morgan Stanley Smith Barney LLC has filed a Rule 144 notice to sell 550 shares of Bio-Rad Laboratories (BIO). The filing indicates two restricted stock lots, dated July 25, 2025 (157 shares) and September 6, 2025 (393 shares), with the notice itself filed on May 11, 2026. This SE

Tone
Neutral 50/100
Event
Market update
Published
28 May 2026 08:10
Source
Stock Titan
Sahm Direct company coverage

Is It Time To Reassess Bio-Rad Laboratories (BIO) After Its Recent 16% Weekly Surge?

Bio-Rad Laboratories (BIO) recently experienced a 16.2% weekly surge, prompting a re-evaluation of its stock valuation. According to Simply Wall St's analysis, the company scores 2 out of 6 on its valuation framework and is considered fairly valued by a Discounted Cash Flow (DCF)

Tone
Neutral 50/100
Event
Balance sheet
Published
24 May 2026 11:09
Source
Sahm
TradingView Direct company coverage

Bio-Rad Laboratories, Inc. Class B Trade Ideas — BOATS:BIO.B

This article aggregates trade ideas for Bio-Rad Laboratories, Inc. (BIO.B) from various traders on TradingView. Ideas range from long positions based on fundamental analysis and technical indicators like the 100 EMA and RSI, to short positions anticipated after a technical break.

Tone
Positive 63/100
Event
Market update
Published
23 May 2026 00:09
Source
TradingView
Sahm Direct company coverage

Elliott Stake Puts Bio-Rad Turnaround Plans And Sartorius Holding In Focus

Elliott Investment Management has acquired a significant stake in Bio-Rad Laboratories, signaling potential pressure for operational, governance, or portfolio changes. This move comes as Bio-Rad faces a mixed share price record and holds a substantial stake in Sartorius. Investor

Tone
Positive 64/100
Event
Deals and strategy
Published
21 May 2026 05:39
Source
Sahm
Sahm Direct company coverage

Why Elliott Sees Hidden Billions Inside Bio-Rad Laboratories

Activist investor Elliott Investment Management has acquired a significant stake in Bio-Rad Laboratories, Inc. and plans to advocate for improved share performance. Bio-Rad's substantial investment in Sartorius, valued at approximately $5 billion, is a key focus for Elliott, repr

Tone
Positive 60/100
Event
Deals and strategy
Published
20 May 2026 03:40
Source
Sahm
TradingView Direct company coverage

Bio-Rad Laboratories, Inc. Class B Trade Ideas — LS:862449

This article compiles various trade ideas and analyses for Bio-Rad Laboratories, Inc. (LS:862449, NYSE:BIO) from different users on TradingView. It includes both long and short positions based on technical indicators like RSI, EMA, and pivot points, as well as fundamental analysi

Tone
Positive 61/100
Event
Market update
Published
16 May 2026 16:39
Source
TradingView
TradingView Direct company coverage

Number of shareholders of Bio-Rad Laboratories, Inc. Class B – LS:862449

This article provides information about the number of shareholders for Bio-Rad Laboratories, Inc. Class B (LS:862449). It appears to be a page from TradingView, presenting financial data and market information for the company. The core content seems to be a placeholder for shareh

Tone
Neutral 50/100
Event
Market update
Published
16 May 2026 04:39
Source
TradingView
FinancialContent Direct company coverage

About Us | Oil & Gas Journal - Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE:BIO) Stock Quote

This article provides detailed stock information for Bio-Rad Laboratories, Inc. (NYSE:BIO), including its current price, trading volume, and performance metrics. It also lists recent news headlines related to the company, focusing on earnings reports, investor conferences, and ot

Tone
Negative 42/100
Event
Earnings
Published
15 May 2026 14:10
Source
FinancialContent
Stock Traders Daily Direct company coverage

(BIO) Movement as an Input in Quant Signal Sets

This article provides an analysis of Bio-rad Laboratories Inc. Class A (NYSE: BIO), indicating weak near and mid-term sentiment but a positive long-term outlook. It presents institutional trading strategies, including position trading, momentum breakout, and risk hedging, along w

Tone
Negative 40/100
Event
Guidance
Published
11 May 2026 21:34
Source
Stock Traders Daily